


BEST AVAILABLE COPY



(11) Publication number:

0 283 140  
A3

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 88301475.5

(51) Int. Cl.4: A 61 K 31/20

(22) Date of filing: 22.02.88

(30) Priority: 09.03.87 GB 8705459

(43) Date of publication of application:  
21.09.88 Bulletin 88/38

(84) Designated Contracting States:  
AT BE CH DE ES FR GB GR IT LI LU NL SE

(68) Date of deferred publication of search report:  
26.07.89 Bulletin 89/30

(71) Applicant: EFAMOL HOLDINGS PLC  
Efamol House Woodbridge Meadows  
Guildford Surrey GU1 1BA (GB)

(72) Inventor: Horrobin, David Frederick  
Efamol Limited Efamol House Woodbridge Meadows  
Guildford Surrey GU1 1BA (GB)

Stewart, John Charles Marshall  
Efamol Limited Efamol House Woodbridge Meadows  
Guildford Surrey GU1 1BA (GB)

(74) Representative: Caro, William Egerton et al  
J. MILLER & CO. Lincoln House 296-302 High Holborn  
London WC1V 7JH (GB)

(54) Compositions and method for treatment of peptic ulcers.

(57) Treatment or prevention of occurrence or reoccurrence of peptic ulcers by administering to a person suffering or at risk of suffering from the same, 1mg to 50g per day, advantageously 10mg to 1g per day, of one or more essential fatty acids selected from the 18:3 and higher acids of the n-6 series and the 18:4 and higher acids of the n-3 series.



European Patent  
Office

# **PARTIAL EUROPEAN SEARCH REPORT**

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

Application number

EP 88 30 1475

## **DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)
X,Y	EP-A-0 195 570 (EFAMOL LTD.) * Column 1, line 15 - column 2, line 13; column 2, line 14 - column 4, line 66; column 9, line 51 - column 10, line 30, claims * --	1-3	A 61 K 31/20
X	EP-A-0 101 294 (EFAMOL LTD.) * Page 2 ,line 6 - page 3, line 24; claims * --	1-3	
X	GUT, vol. 27, 1986, pages 239-242; D. HOLLANDER et al.: "Dietary essential fatty acids and the decline in peptic ulcer disease - a hypothesis" * Whole document * --	1-3	
X	J. LAB. CLIN. MED. vol. 102, 1983, pages 340-351 ./.		

TECHNICAL FIELDS  
SEARCHED (Int. Cl. 4)

A 61 K

## **INCOMPLETE SEARCH**

The Search Division considers that the present European patent application does not comply with the provisions of the European Patent Convention to such an extent that it is not possible to carry out a meaningful search into the state of the art on the basis of some of the claims.

Claims searched completely: 1-3

Claims searched incompletely:

Claims not searched: 4-6

Reason for the limitation of the search:

Method for treatment of the human or animal body by surgery or therapy (See art. 52(4) of the European Patent Convention)

Category	DOCUMENTS CONSIDERED TO BE RELEVANT		CLASSIFICATION OF THE APPLICATION (Int. Cl. 8)
	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
	<p>* Summary; page 41, left-hand column, line 19 - page 42, right-hand column, line 2 *</p> <p>-----</p>	1-3	
			TECHNICAL FIELDS SEARCHED (Int. Cl. 8)


DOCUMENTS CONSIDERED TO BE RELEVANT	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 8)
"Arachidonic gastric mucosa y: sequential ic and func-	1-3	
page 341, 349-350 *		
l. 100,		
"Arachidonic it gastric l injury"	1-3	
section "re- first section discussion" -		TECHNICAL FIELDS SEARCHED (Int. Cl. 8)
OL. vol. 22, ; pages		
"Cytoprotec- essential ulfate"	1-3	
1 *		
OL., vol. 20 ges 41-48 Protection l mucosa by		
section "Intro- left-hand page 44, line 15 - column, ft-hand co- e 46, right- 13 *	1-3	
l 1; 1987		
ic role of ibolites in stasis"		

## METHOD FOR TREATMENT OF PEPTIC ULCERS

ons and methods for the treatment or prevention of occurrence of

## FOUND

First is that considerable interest has been shown in recent years in  
s in medicine.  
levels of prostaglandins are required it is not usually practical to  
indins such as PGE1 and PGE2 to patients. Consequently, consider-  
of prostaglandin precursors including linolenic acid, gamma-linolenic  
; acid (DGLA).  
body is believed to be as shown in the following diagram.




gamma-linolenic acid (GLA) and then to DGLA and AA, the latter step being irreversible. The conversion of linoleic acid to GLA is a limiting step, adequate in the young and healthy body but often inadequate in ageing or in many diseased states.

DGLA is the key substance. GLA is almost completely and very rapidly converted in the body to DGLA and so for practical purposes the oral administration of DGLA and GLA amounts to the same thing. DGLA can be converted to a storage form, changed to arachidonic acid and thence to PGs of the 2-series, or converted to PGs of the 1-series.

The second part of the background is increasing awareness of the significance of the essential fatty acids in themselves, in which considerable general interest has been shown in recent years. Primarily in the acids of the n-6 series both as such and in relation to prostaglandin metabolism, but also in the acids of the n-3 series. The n-6 acids in particular are required in the body for the structure of membranes in and around cells, being believed to be necessary for maintaining normal flexibility, fluidity and permeability of such membranes, and while less is known of the role of the n-3 series acids they are equally present.

The pathways of metabolism of the n-6 essential fatty acids and the related n-3 acids sharing, it is believed, common enzymes in the two pathways, are:



The pathways are not normally reversible nor in m.

The acids, which naturally are of the all-cis configuration corresponding octadecanoic, eicosanoic or docosanoic 4,7,10,13,16,19-tetacosanoic acid, but numerical difference of 2 is convenient. Initials, for example, DHA for 22:6 n-3 serve when n-3 and n-6 acids of the same chain length more or less common use in the n-6 series are as shown in the literature simply to linolenic acid, especially in the body, the n-3 acids are metabolised preferentially of alpha-linolenic acid (18:3 n-3) are low and 18:4 n-3 the n-6 acids are normally present in moderate amounts, being apparently converted to dihomogamma-linolenic acid. In both series the air more rapid than the desaturations

### SPECIFIC BACKGROUND

Pepic ulcers of the stomach and duodenum are caused or by several different drugs. The two most effective antagonists and the prostaglandin (PG) analogues. It histamine and so reducing acid secretion. The PG analogues part by increasing the defences of the gastroduodenal process which has been termed "cytoprotection".

Patients whose ulcers have been healed by one susceptible to a recurrence of peptic ulceration. This risk of adverse effects. There is therefore a need to combat long term ulcer recurrence.

One possible approach would be to increase the mucosa. If PGs are indeed cytoprotective, this would be to be increased. One limited way of doing this might be Gamma-linolenic acid (GLA) to dihomogamma-linolenic acid of potentially cytoprotective prostaglandins. Unfortunately high cholesterol levels and diabetes are known to reduce that, especially in adult humans following lifestyles in gastro-duodenal PG production is inadequate. The blood provision of GLA, DGLA, or AA, GLA is rapidly converted produce PGs from the DGLA and AA precursors.

In tests in normal individuals we have shown that primrose oil can indeed raise gastric PG levels significantly even in the presence of aspirin which is known to inhibit PG levels and those stimulated by evening primrose oil with the drop present GLA was able to produce a significant

PG synthesis from DGLA and AA can be inhibited, such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for the cytochrome P-450. DGLA and DHA to people would reduce PG synthesis gastric mucosa to damage.

One measure of such susceptibility is to administer gastro-duodenal mucosa enough to cause small amounts the loss of blood in the laeres. We therefore administer individuals and compared the blood loss. To our significantly reduce administering the fish oil, which

acid components, the gamma-linolenic and linoleic as the main fatty acid components, the oleic acid content being at desired a major proportion. Seed oil extracts appear to have a stabilizing effect upon dihomogamma-linolenic acid if present.

Natural sources of 22:4 and 22:5 n-6 acids include adrenal glands (22:5) and kidneys (22:4) obtained from slaughter houses, and 22:4 in the fat of the American Snapping Turtle. The n-3 acids are available from fish oils, particularly 20:5 n-3 and 22:6 n-3. The acids can be isolated from these sources by, for example, saponification under mild non-oxidising conditions followed by preparative gas liquid chromatography. Synthesis of the acids is difficult but not impossible and provides another source.

Advantageously, a preservative is incorporated into the preparations; alpha-tocopherol in concentration of about 0.1% by weight has been found suitable for the purpose.

## EXAMPLES

The following are examples of medicaments produced according to the invention and their administration according to the method of the invention, as soft or hard gelatine capsules produced by the conventional methods and suited to oral administration as the most convenient method of delivering the active compounds to the stomach and duodenum. Other method of administration leading to enhanced levels therein are, however, not excluded.

1. Capsules containing 1g fish oil comprising 25% EPA and 7% DHA by weight, 8 per day.
2. Capsules containing 500mg evening primrose oil comprising 9% GLA by weight, 12 per day.
3. Capsules containing 2g of a mixture of the fish oil from 1. and the evening primrose oil from 2. in equal proportions by weight, 6 per day.

4. Capsules containing 200mg ethyl-EPA, 200mg ethyl-DHA, 200mg ethyl-AA and 200mg ethyl-DGLA, 6 per day.
5. In a bland diluent, an EPA concentrate containing by weight 60% EPA and 15% DHA, 6g per day of the concentrate.

Similarly:

6. 5g/day of pure GLA
7. 10g/day of pure EPA
8. 2g/day of pure DHA
9. 1g/day of pure AA
10. 4g/day of pure DGLA
11. Capsules containing 200mg EPA, 100mg GLA and 50mg each of DGLA, AA, DHA, 22:4 n-6, 22:5 n-6, 18:4 n-3 and 20:4 n-3, 4 per day

## Claims

1. The use of one or more essential fatty acids selected from the 18:3 and higher acids of the n-6 series and the 18:4 and higher acids of the n-3 series, for the preparation of medicaments for the treatment or prevention of occurrence or reoccurrence of peptic ulcers by administration of 1mg to 50g per day, advantageously 10mg to 1gm per day, of said acids.
2. The use of essential fatty acids selected from the 18:3, 20:3, 20:4, 22:4 and 22:5 acids of the n-6 series and the 18:4, 20:4, 20:5, 22:5 and 22:6 acids of the n-3 series as in claim 1.
3. The use according to claim 1 or 2, wherein the said acids are in the form of their salts, amides, esters, alcohols, phospholipids or pharmaceutically acceptable and physiologically equivalent derivatives.
4. Treatment or prevention of occurrence or reoccurrence of peptic ulcers by administering to a person suffering or at risk of suffering from the same, 1mg to 50g per day, advantageously 10mg to 1g per day, of one or more essential fatty acids selected from the 18:3 and higher acids of the n-6 series and the 18:4 and higher acids of the n-3 series.
5. Treatment according to claim 4, wherein the acids administered are essential fatty acids selected from the 18:3, 20:3, 20:4, 22:4 and 22:5 acids of the n-6 series and the 18:4, 20:4, 20:5, 22:5 and 22:6 acids of the n-3 series.
6. Treatment according to claim 4 or 5, wherein the said acids are in the form of their salts, amides, esters, alcohols, phospholipids or pharmaceutically acceptable and physiologically equivalent derivatives.

3 acids may be able to protect the gastro-duodenal mucosa in at least act by some quite different mechanism which is that the administration of such polyunsaturated fatty acids, either alone or in combination as having therapeutic value in the are known to be very safe in long term administration at the advantages over other available techniques. Other possible 22:4 n-6, 22:5 n-6, 18:4 n-3, 20:4 n-3, 22:5 n-3. The parent acid are unlikely to be of value except at analgesic dose

ulation.  
in the use of one or more essential fatty acids selected from the 18:4 and higher n-3 series acids for the preparation of occurrence or reoccurrence of peptic ulcers by administration of 1g per day, of said acids.

13. 20:3, 20:4, 22:4, 22:5, acids of the n-6 series and the 18:4, 20:4, 20:5, 22:5, acids of the n-3 series as in claim 1.

14. The method of treatment or prevention of peptic ulcers by purposes in such amounts.

pharmaceutically acceptable and physiologically equivalent gamma-linolenic acid and dihomogamma-linolenic acid, and as including reference to the acids when in the form of such free acids. Equivalence is demonstrated by entry into the acids corresponding to those of the acids themselves or their indication of useful derivatives is by their having the valuable sion can be shown directly by gas chromatographic analysis issue by standard techniques, for example those of Polick et al s" Ed. Perkins, American Oil Chemist Society, Champaign.

atives of gamma-linolenic acid and dihomogamma-linolenic /ceride esters and allyl (eg. C1 to C4) esters, alcohols and

may be produced for use in the invention by associating the derivatives, with an acceptable pharmaceutical vehicle. It is, at least the gamma-linolenic acid into compositions in the linolenic acid content, hence references to "oil" herein or oils having a high gamma-linolenic acid content are low in amounts of dihomogamma-linolenic acid. One source of it. Primrose species such as *Oenothera biennis* L. and com containing gamma-linolenic acid (about 8%) and linoleic together with other glycerides (percentages based on total acid are Borago species such as *Borago officinalis* which, by fermentation promise a fungal oil source. u of the conventional methods of extraction such as cold the seed, or solvent extraction. i the form of methyl esters shows the relative proportions.

an be used as such or can, for example, if desired, be ing the triglycerides of gamma-linolenic and linoleic as the

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.